Sedia Biosciences Merges With Floragenex | GenomeWeb

NEW YORK (GenomeWeb) – Point-of-care diagnostics developer Sedia Biosciences has merged with genomic testing services provider Floragenex, the companies announced today.

Floragenex will now operate as a newly established subsidiary of Sedia, and will continue to offer its genomic services and solutions to life scientists. Sedia will also continue to offer its own Asanté assays for HIV and other infectious agents. Sedia CEO Roger Gale will remain CEO of the combined companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.